Trial · NCT04310592
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
NCT04310592, Phase 1, Terminated, Celularity Incorporated
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Natural Killer Cell (CYNK-001) Infusions in Adults with AML. Trials, record NCT04310592. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04310592
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Natural Killer Cell (CYNK-001) Infusions in Adults with AML
- NCT number
- NCT04310592
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 27 participants, actual
- Lead sponsor
- Celularity Incorporated
- Conditions
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type, Neoplasms, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Alkylating Agents, Antimetabolites, Antineoplastic, Antiviral Agents, Analgesics, Non-narcotic, Anti-infective Agents, Analgesics, Peripheral Nervous System Agents, Hematologic Diseases, Hematologic Neoplasms, Leukemia in Remission, Relapsed Adult AML, Refractory AML
- Interventions
- CYNK-001
- First posted
- 2020-03-17
- Last updated
- 2024-12-12
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants who experience a Dose-limiting Toxicity (DLT) in MRD positive AML patients | Day +28 | The number of participants who experience a DLT will be measured. |
| Primary | Number of Participants who experience a Dose-limiting Toxicity (DLT) in Relapsed/Refractory AML patients | Day +28 | The number of participants who experience a DLT will be measured. |
| Primary | Determine the Maximum Tolerated Dose (MTD) or Maximum Planned Dose (MPD) of CYNK-001 in MRD positive AML patients | up to 28 days | The maximum dose safely administered for the treatment of patients with AML. |
| Primary | Determine the Maximum Tolerated Dose (MTD) or Maximum Planned Dose (MPD) of CYNK-001 in Relapsed/Refractory AML patients | up to 28 days | The maximum dose safely administered for the treatment of patients with AML. |
| Primary | Frequency and Severity of Adverse Events (AEs) | up to 12 months | Frequency and severity of Adverse Events will be evaluated. |
| Secondary | Number Participants who experience Minimal Residual Disease (MRD) Response | up to 12 months | The number of participants who convert from MRD positive to MRD negative in the MRD positive arm. |
| Secondary | Time to MRD Response | up to 12 months | The time it takes to convert from MRD positive to MRD negative in the MRD positive arm. |
| Secondary | Duration of MRD Response | up to 12 months | The measure of how long participants remain MRD negative in the MRD positive arm. |
| Secondary | Progression-free Survival (PFS) | up to 12 months | Date of first CYNK-001 infusion to date of disease progression in the MRD positive arm. |
| Secondary | Time to Progression (TTP) | up to 12 months | Date of first CYNK-001 infusion to date of disease progression in the MRD positive arm. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04310592
GET https://conductscience.org/api/trials/v1/NCT04310592/registered